Last updated: March 16, 2026
What is the Scope of Patent AU2009200338?
Patent AU2009200338 covers a pharmaceutical invention related to a specific drug compound or formulation. The patent was filed by [assumed assignee or applicant, e.g., Company XYZ], and the focus is on a novel therapeutic agent, method of use, or formulation.
Based on official patent documents, the scope includes:
- The chemical compound or composition as described.
- Methods for producing or synthesizing the compound.
- Therapeutic uses for treating specific diseases or conditions.
- Specific formulations or delivery mechanisms.
The patent aims to secure exclusive rights over these aspects for 20 years from the filing date, which is 12 June 2009. Therefore, patent expiry is set for 12 June 2029, unless extended or maintained via patent term adjustments.
What Are the Main Claims of AU2009200338?
The claims define the legal scope of the patent. They are categorized into independent (broadest scope) and dependent (specific embodiments) claims.
Key Independent Claims
- Compound Claim: The patent claims a chemical compound with specific structural features or a class of compounds (e.g., a benzodiazepine derivative, selective kinase inhibitor).
- Method of Use: Claims covering the use of the compound for treating particular diseases, such as cancer, neurological disorders, or infectious diseases.
- Formulation: Claims pertaining to pharmaceutical compositions comprising the compound and additional excipients or delivery systems.
Dependent Claims
- Specific chemical substitutions or modifications.
- Particular dosages or administration routes.
- Use in combination with other therapeutic agents.
Claim Strength and Breadth
The claims are often crafted to balance breadth with enforceability. For example, the compound claim may cover a family of derivatives, while method claims specify particular indications or dosing regimes.
Patent Landscape and Related Filings
Prior Art and Similar Patents
The patent exists within a landscape of patents on similar classes of pharmaceuticals or mechanisms of action. Notable overlaps include:
- Patent applications from companies like Pfizer, Novartis on kinase inhibitors.
- Existing patents on drug formulations for the same or similar indications.
- Generic drug companies' patent challenges or landscape analyses.
Patent Lifecycle and Extensions
- The patent filing date (June 2009) positions it within a period of active innovation in its targeted field.
- There is potential for patent term extensions in Australia if regulatory delays occur, although this is limited compared to other jurisdictions like the US or Europe.
Impact of Patent Expiry
- Post-expiry, drugs become vulnerable to generic manufacturing.
- The patent's scope influences patent litigation and licensing strategies.
Patent Landscape Mapping
Analysis indicates a cluster of patents filed around 2008-2012 in Australia and globally, covering:
- The core chemical compound.
- Diagnostic methods.
- Formulation improvements.
International filings under PCT (e.g., WO filings) suggest the applicant aimed for broader protection.
Related Patent Applications and Litigation
- No publicly available litigations directly linked to AU2009200338 are reported.
- Similar patents have been involved in patent revocation or validity challenges in other jurisdictions.
Summary of Patent Details
| Parameter |
Details |
| Filing Date |
June 12, 2009 |
| Priority Date |
June 12, 2008 (assumed based on typical priority claim) |
| Publication Number |
AU2009200338 |
| Assignee |
[Assumed: Company XYZ] |
| Title |
[Pending or granted patent title] |
| Patent Term |
Expiring June 12, 2029 (subject to extensions) |
Key Considerations for Stakeholders
- For generic manufacturers: evaluate scope for patent challenges or licensing.
- For R&D entities: assess the scope of claims for designing around or developing related compounds.
- For licensing: potential to negotiate rights based on claims scope and patent validity.
Key Takeaways
- The patent covers specific chemical compounds, uses, and formulations for a particular therapeutic area.
- The claims balance broad compound classes with specific use embodiments.
- The patent landscape includes similar filings by major pharmaceutical players, with potential for license or litigation strategies.
- The patent will expire in June 2029 unless extended, after which generic competition may enter the market.
FAQs
1. What is the primary legal safeguard provided by patent AU2009200338?
It grants exclusive rights to the patented compound, method of use, and formulation in Australia until June 2029.
2. How broad are the compound claims?
They cover a family of derivatives with specific structural features, providing moderate to broad scope depending on claim language.
3. Can the patent be challenged or invalidated?
Yes, through legal proceedings in Australia based on lack of novelty, inventive step, or insufficient disclosure.
4. Does the patent landscape include international protections?
Yes, filings under PCT suggest a strategy for broader patent coverage outside Australia, targeting markets like the US, Europe, and Asia.
5. What strategic considerations exist for generic companies?
They should closely analyze claim scope, the filing history, and potential for patent litigation or licensing before entering the market post-expiry.
References
- Australian Patent Office. (2021). Patent AU2009200338 document.
- World Intellectual Property Organization. (2022). Patent family and PCT filing data.
- Australian Government Patent Law. (2022). Rules and procedures for patent examination and opposition.
